Experienced in Hypophosphatemia

Patrick Flamen

Brussels, BRU, BE 
Experienced in Hypophosphatemia
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Patrick Flamen practices in Brussels, Belgium. Flamen is rated as an Experienced expert by MediFind in the treatment of Hypophosphatemia. Their top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Breast Cancer, Liver Embolization, and Hepatectomy.

Their clinical research consists of co-authoring 118 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Hypophosphatemia.

Locations

Brussels, BRU, Belgium
Other Locations
Belgium
Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 2
Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer
Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Other
Study Phase: Not Applicable
View 2 Less Clinical Trials

118 Total Publications

Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted Approaches.
Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted Approaches.
Journal: Seminars in nuclear medicine
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Flamen's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile